QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)
Free KTTA Stock Alerts
$7.11
-0.04 (-0.56%)
(As of 09:57 AM ET)
Compare
Today's Range
$7.11
▼
$7.11
50-Day Range
$5.80
▼
$8.75
52-Week Range
$5.25
▼
$17.40
Volume
279 shs
Average Volume
9,841 shs
Market Capitalization
$7.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media
KTTA stock logo

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Stock Price History

KTTA Stock News Headlines

April 19, 2024 | americanbankingnews.com
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 0.4%
February 13, 2024 | finance.yahoo.com
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 8, 2024 | finance.yahoo.com
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
January 2, 2024 | msn.com
Pasithea Jumps as FDA Grants IND Status to Cancer Treatment
January 2, 2024 | markets.businessinsider.com
Pasithea Therapeutics' IND Application For PAS-004 Gets FDA Acceptance
January 2, 2024 | seekingalpha.com
Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study
January 2, 2024 | finance.yahoo.com
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 1, 2024 | benzinga.com
Pasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and Dates
December 28, 2023 | finance.yahoo.com
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
December 19, 2023 | finance.yahoo.com
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
December 13, 2023 | msn.com
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
December 11, 2023 | msn.com
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
December 11, 2023 | markets.businessinsider.com
Pasithea Announces Positive In Vivo Preclinical Data For PAS-004
December 11, 2023 | msn.com
Pasithea stock soars as high as 190% on preclinical data
December 11, 2023 | investorplace.com
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
December 11, 2023 | finance.yahoo.com
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
November 29, 2023 | finance.yahoo.com
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
November 29, 2023 | msn.com
Pasithea stock jumps 12% on update for anti-tumor drug PAS-004
November 29, 2023 | markets.businessinsider.com
Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development
November 29, 2023 | finance.yahoo.com
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
November 9, 2023 | finance.yahoo.com
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
September 14, 2023 | finance.yahoo.com
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
September 7, 2023 | finance.yahoo.com
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 1, 2023 | finance.yahoo.com
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
July 20, 2023 | benzinga.com
What's Happening With Pasithea Therapeutics Stock Today?
See More Headlines
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Next Earnings (Estimated)
6/27/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KTTA
CUSIP
N/A
CIK
1841330
Web
www.pasithea.com
Phone
702-514-4174
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,960,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.04%
Return on Assets
-45.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.34
Quick Ratio
6.34

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
370.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$22.46 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
1,040,000
Free Float
895,000
Market Cap
$7.40 million
Optionable
Not Optionable
Beta
0.88
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Lawrence Steinman BA (Age 76)
    M.D., Ph.D., Co-Founder, MD & Executive Chairman
    Comp: $250k
  • Dr. Tiago Reis Marques M.D. (Age 47)
    Ph.D., CEO & Director
    Comp: $539.25k
  • Mr. Daniel H. Schneiderman (Age 46)
    Chief Financial Officer
    Comp: $327.91k
  • Dr. Yassine Bendiabdallah Ph.D. (Age 40)
    COO & Head of UK Clinics
  • Dr. Graeme Currie Ph.D.
    Chief Development Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed in 2024?

Pasithea Therapeutics' stock was trading at $7.40 at the beginning of the year. Since then, KTTA shares have decreased by 3.9% and is now trading at $7.11.
View the best growth stocks for 2024 here.

When is Pasithea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024.
View our KTTA earnings forecast.

When did Pasithea Therapeutics' stock split?

Pasithea Therapeutics's stock reverse split before market open on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTTA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends